May 05–08, 2024 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers:
Laura M. Walker and Paul W. H. I. Parren

-
Scientific Organizers: Laura M. Walker and Paul W. H. I. Parren
Laura M. Walker
Paul W. H. I. Parren
***Meeting program subject to change.
Available Formats: = In PersonMerchandise Options
Registration Options
Booking Function
Fundraising
Sunday, May 5, 2024
Monday, May 6, 2024
Session Chair
Session Chair
Mining Antibody Biology for Novel Functionalities and Therapeutic Antibody Development
Session Chair
The Science of FcRn: Tuning Antibody and Antigen Degradation
Engineering Therapeutic Antibodies to Optimize Half-Life and Function
Engineered IgA Antibody Therapeutics
Short Talk: Short Talk: Conversion of S. Aureus Specific IgG Into IgM Broadens the Reactivity to Other Bacterial Species
Professor and Chair
Director and Principal Scientist
Professor
Head of Founder Strategy and Operations
Session Chair
Engineered Antibodies for Treating Emerging Viral Infections
Multispecific Immunotherapies for Infectious Disease
Unraveling Correlates of Immunity with Systems Serology in Drug Development and Vaccines
Short Talk: Short Talk: Broad Coverage of Antibiotic-Resistant Klebsiella Pneumoniae by Multi-Specific Antibodies Against the Lipopolysaccharide O-Antigen
Short Talk: Short Talk: Structural Insights into Multimeric Recognition by Glycan-Directed Broadly Neutralizing Antibodies Targeting HIV-1 Envelope Glycoprotein
Tuesday, May 7, 2024
Session Chair
Bispecific Antibodies for Recruiting Alternative Immune Cells for Cancer Therapy
Engineering Antibodies and Fusion Proteins for Disease Targeting
Interplay Between the Tumor Microenvironment and the Antibody Fc in Optimizing Therapy
Conditional Activation of Protein Therapeutics in the Tumor Microenvironment’
Short Talk: Short Talk: Customized Ovarian Cancer Therapy Using in vivo Assembled Bi-Specific Antibodies Targeting Her2 and FSHR
Short Talk: Short Talk: A Novel Method for Generating Regulated Cytokine Therapeutics: Safety and Activity of a Conditionally Active cLAG3-IL2 in a Simple Antibody Format
Session Chair
Predicting Antibody Developability using Interpretable Machine Learning
Improved Computational Epitope Profiling Using Structural Models Identifies a Broader Diversity of Antibodies that Bind to the Same Epitope
Addressing the Antibody Germline Bias and its Effect on Language Models for Improved Antibody Design
Multi-Modal, Broadly Neutralizing Antibodies to SARS-CoV-2 and Influenza Discovered via High-Throughput Native Pairing of BCRs From Bulk B Cells
Industrializing Therapeutic Antibody Design. Generative AI Enables Intentional Antibody Engineering Over Random Chance Discovery
From Mice to Men: Energy-Based Antibody Humanization
Computational Optimization of an Anti-HEL Antibody Leads to Increased Antibody Thermostability and Affinity
Computational Insights and New Strategies for Advanced Antibody Engineering
Session Chair
Avidity Engineering of Therapeutic Antibodies
Multipecific, IgM-based, T Cell Engagers for Treating Cancer
Avid and Multispecific Biologics for Global Health
Rational Design of Combinatorial Targeting to Optimize Checkpoint Blockade
Short Talk: Short Talk: Exploring Interaction Rules for Multispecific Targeting using the HexElect Antibody Format
Wednesday, May 8, 2024
Session Chair
Advances Beyond Monoclonal Antibodies
Prophylaxis and Treatment of Infectious Disease with Half-Life Extended Neutralizing Antibodies
TRYBE: An Fc-Free Antibody Format with Three Monovalent Targeting Arms and Engineered for Long in vivo Half-Life
Short Talk: Short Talk: Development of a Machine Learning (ML) Designed Anti-TSLP Antibody for the Treatment of Asthma
Short Talk: Short Talk: Translatability of Findings from Cynomolgus Monkey to Human Suggests a Mechanistic Role for IL-21 in Promoting Immunogenicity to an Anti-PD-1/IL-21 Mutein Fusion Protein
Session Chair
Rational Design of Antibody Therapeutics via Deep Learning
Brain Delivery of Therapeutic Proteins with Fc-Engineered Molecules
Short Talk: Short Talk: Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-Throughput Yeast-Based Platform
Short Talk: Short Talk: Cytokine Receptor-Targeting Chimeras: Unveiling Dual Modalities for Targeted Protein Degradation and Immune Cell Engagement
Thursday, May 9, 2024
Subscribe for Updates